CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Head of Data at CLSA

Vincent Kwan

My Perspective: Balancing Generative AI's Potential with Prudence in Investment Banking

Vincent Kwan

Vincent Kwan

The financial sector, renowned for embracing technological advancements, is currently captivated by Generative AI's potential. Numerous experts have emerged, with firms, consultancies, and IT organizations positioning themselves as domain specialists. However, as past trends like blockchain have shown, hasty adoption without a thorough understanding can lead to unforeseen challenges.


Generative AI, celebrated for its ability to generate content from recognized patterns, is undeniably transformative. Yet, its current optimal use is as a supplementary tool rather than an infallible solution. While "Generative" implies innovation, it's essential to recognize that it doesn't ensure perfection. At its core, Generative AI, like most AI models, is based on statistical models. Despite its intricate design using billions of parameters, its predictions are more probabilistic in certain scenarios due to the nature of its training, introducing an inherent margin of error.


This margin of error in Generative AI differs from traditional software errors. While conventional programming issues, often traceable, arise from deterministic processes like incorrect specifications or flawed implementation, errors in Generative AI can emerge even when the system is functioning as designed due to its probabilistic predictions. Regulations such as the GDPR require that AI decision-making processes be transparent, accountable, and open to challenges to protect individuals' data rights. Researchers are still navigating the complexities of instilling explainability into AI outputs. For pivotal institutions like Investment Banks, introspection is vital: Is Generative AI, with its sometimes opaque decision-making process, genuinely ready for deployment?


Generative AI, celebrated for its ability to generate content from recognized patterns, is undeniably transformative




While Proofs of Concept provides valuable insights, any substantial implementation demands rigorous testing and meticulous scrutiny.


When applying Generative AI to the stringently regulated realm of Financial Investment Advisory, many challenges arise. Many countries mandate strict regulations in this sector to protect investors and uphold financial market integrity. Decisions here carry significant financial, legal, and ethical implications. Generative AI can recognize patterns and insights from data that might not be evident to humans, suggesting impactful strategies. Yet, given the inherent risks and accountabilities, the need for human intervention and oversight remains indispensable. In such domains, Generative AI should ideally augment human expertise, not supplant it.




To better understand the practical implications of Generative AI in investment banking, let's examine some specific applications:


• M&A Forecasting: Generative AI can create hypothetical merger scenarios based on past data, offering insights into potential M&A outcomes. However, while it provides quantitative insights, integrating qualitative factors such as organizational culture remains a challenge, potentially affecting its accuracy.


• Trade Optimization and Strategy Development: Using Generative AI to simulate past trades helps traders spot successful patterns and improve their strategies. While traders make the final decisions, insights from Generative AI offer them a data-driven perspective, aiding but not guaranteeing smarter investments.


• Enhanced Risk Assessment and Fraud Detection: Generative AI can simulate various market conditions, offering deep risk assessment insights. However, its challenge lies in events for which there is no historical data, potentially missing details that a banking expert would consider.


In investment banking, the potential of Generative AI is remarkable. It promises transformative changes, but addressing its intrinsic margin of error remains crucial. With diligent design and continuous improvements, this error and uncertainty can be significantly reduced e.g. by embarking better quality and quantity of data for training and fine-turning. When managed effectively, Generative AI can evolve from a supporting role to being a central player in banking processes. This progression doesn't overshadow the significance of human-AI collaboration; instead, it emphasizes that both AI and humans are essential for the future. Together, they herald a promising and advanced era in investment banking.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/my-perspective-balancing-generative-ai-s-potential-with-prudence-in-investment-banking-nwid-1582.html